<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406092</url>
  </required_header>
  <id_info>
    <org_study_id>ML28964</org_study_id>
    <nct_id>NCT02406092</nct_id>
  </id_info>
  <brief_title>Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A</brief_title>
  <official_title>An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC)
      administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL)
      (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell
      lymphoma (DLBCL) (treatment plus 24 months of follow-up).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 13, 2015</start_date>
  <completion_date type="Anticipated">July 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Administration-Associated Reactions (AARs)</measure>
    <time_frame>Within 24 hours of each rituximab SC administration (maximum treatment duration up to 32 months for FL participants and up to 8 months for DLBCL participants)</time_frame>
    <description>AARs defined as all related adverse events (AEs) occurring within 24 hours of rituximab SC administration, including infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS) as Assessed by Investigator According to International Working Group (IWG) Response Criteria</measure>
    <time_frame>From first dose of rituximab intravenous (IV) and SC until first occurrence of progression or relapse (up to end of induction treatment [up to 8 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Assessed by Investigator According to IWG Response Criteria</measure>
    <time_frame>From first dose of rituximab IV and SC until first occurrence of progression or relapse (up to end of induction treatment [up to 8 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first dose of rituximab IV and SC until death from any cause (up to end of induction treatment [up to 8 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS) as Assessed by Investigator According to IWG Response Criteria</measure>
    <time_frame>From the date of the initial complete response (CR)/complete response unconfirmed (CRu) until date of relapse or death from any cause (up to end of induction treatment [up to 8 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CR/CRu as Assessed by Investigator According to IWG Response Criteria</measure>
    <time_frame>From first dose of rituximab until first occurrence of progression or relapse (up to end of induction treatment [up to 8 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Professional Questionnaire Score</measure>
    <time_frame>End of treatment (Month 24 for FL participants and Month 8 for DLBCL participants)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Rituximab Administration Questionnaire (RASQ) Score</measure>
    <time_frame>FL participants: Baseline, end of induction treatment/early termination (ET) (up to 8 months), end of maintenance treatment/ET (up to 24 months); DLBCL participants: Baseline, end of treatment/ET (up to 8 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP [cyclophosphamide+doxorubicin+vincristine+prednisone], CVP [cyclophosphamide+vincristine+prednisone] or FC [fludarabine+cyclophosphamide]) during induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab SC 1400 mg</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>MabThera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be administered as per standard local practice.</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin will be administered as per standard local practice.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine will be administered as per standard local practice.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone will be administered as per standard local practice.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine will be administered as per standard local practice.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed, cluster of differentiation (CD)20+ DLBCL or CD20+ follicular
             NHL grade 1 to 3a, according to the world health organization (WHO) classification
             system

          -  Currently being treated with rituximab IV in the Induction or Maintenance setting,
             having received at least one full dose of rituximab IV, defined as standard full dose
             of rituximab IV 375 milligrams per square meter (mg/m^2) administered without
             interruption or early discontinuation because of tolerability issues

          -  Expectation and current ability for the participants to receive at least four
             additional cycles of treatment during the Induction phase or six additional cycles of
             treatment during the Maintenance phase (participants with follicular NHL)

        Exclusion Criteria:

          -  Transformed lymphoma or FL IIIB

          -  History of other malignancy that could affect compliance with the protocol or
             interpretation of results. This includes a malignancy that has been treated but not
             with curative intent, unless the malignancy has been in remission without treatment
             for greater than or equal to (&gt;/=) 5 years prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Dorban CHU Annaba, Service d'Hématologie</name>
      <address>
        <city>Annaba</city>
        <zip>23000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward</name>
      <address>
        <city>Blida</city>
        <zip>09000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EHU Oran, Service d'Hématologie et de Thérapie Cellulaire</name>
      <address>
        <city>Oran</city>
        <zip>31000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie</name>
      <address>
        <city>Tizi Ouzou</city>
        <zip>15000</zip>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU 20 Aout Service D'Onco-Hematologie Pediatrique</name>
      <address>
        <city>Casablanca</city>
        <zip>20100</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique AlMadina; Service hematologie</name>
      <address>
        <city>Casablanca</city>
        <zip>20340</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Uni Ire de Marrakech; Oncologie-Hématologie</name>
      <address>
        <city>Marrakech</city>
        <zip>40000</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ibn Sina Rabat Service de medecine interne</name>
      <address>
        <city>Rabat</city>
        <zip>10090</zip>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Fattouma Bourguiba, Monastir; Service d'hématologie</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hédi Chacker; Service d'hématologie</name>
      <address>
        <city>Sfax</city>
        <zip>3025</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Farhat Hached; Service d'hématologie</name>
      <address>
        <city>Sousse</city>
        <zip>4000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aziza Othmana Hospital; Clinical Haematology</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Militaire d'instruction de Tunis; Service d'hématologie</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Morocco</country>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

